Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

Peripheral neuropathies

Establishing common clinical research standards for CIDP

Nature Reviews Neurology volume 7, pages 250–251 (2011)Cite this article

Subjects

Various clinical scores are available to assess the outcome of chronic inflammatory demyelinating polyneuropathy (CIDP), but these existing scales have some major limitations. A novel, simple scoring system—the CIDP disease activity status—incorporates the concept of disease activity as a feature that informs the long-term outcome in CIDP patients.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Lunn, M. P. & Willison, H. J. Diagnosis and treatment in inflammatory neuropathies. J. Neurol. Neurosurg. Psychiatry 80, 249–258 (2009).

    CAS  PubMed  Google Scholar 

  2. Köller, H., Kieseier, B. C., Jander, S. & Hartung, H. P. Chronic inflammatory demyelinating neuropathy. N. Engl. J. Med. 352, 1343–1356 (2005).

    Article  Google Scholar 

  3. Hughes, R. et al. Intravenous immune globulin (10% caprylate-chromatography purified) for the treatment of chronic inflammatory demyelinating polyradiculoneuropathy (ICE study): a randomised placebo-controlled trial. Lancet Neurol. 7, 136–144 (2008).

    Article  CAS  Google Scholar 

  4. Gorson, K. C. et al. Chronic inflammatory demyelinating polyneuropathy disease activity status: recommendations for clinical research standards and use in clinical practice. J. Peripher. Nerv. Syst. 15, 326–333 (2010).

    Article  Google Scholar 

  5. RMC Trial Group. Randomised controlled trial of methotrexate for chronic inflammatory demyelinating polyradiculoneuropathy (RMC trial): a pilot, multicentre study. Lancet Neurol. 8, 158–164 (2009).

  6. Hughes, R. A. et al. Intramuscular interferon beta-1a in chronic inflammatory demyelinating polyradiculoneuropathy. Neurology 74, 651–657 (2010).

    Article  CAS  Google Scholar 

  7. van Schaik, I. N. et al. Pulsed high-dose dexamethasone versus standard prednisolone treatment for chronic inflammatory demyelinating polyradiculoneuropathy (PREDICT study): a double-blind, randomised, controlled trial. Lancet Neurol. 9, 245–253 (2010).

    Article  CAS  Google Scholar 

  8. Neogi, T. & Felson, D. T. Composite versus individual measures of disease activity in rheumatoid arthritis. J. Rheumatol. 35, 185–187 (2008).

    PubMed  Google Scholar 

  9. Stübgen, J. Tumor necrosis factor-α antagonists and neuropathy. Muscle Nerve 37, 281–292 (2008).

    Article  Google Scholar 

  10. Hughes, R. A. Treating nerves: a call to arms. J. Peripher. Nerv. Syst. 13, 105–111 (2008).

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Neurology, Heinrich-Heine-University, Moorenstrasse 5, Düsseldorf, 40225, Germany

    Hans-Peter Hartung & Helmar C. Lehmann

  2. Institute of Infection, Immunity and Inflammation, College of Medical, Veterinary and Life Sciences, University of Glasgow, Sir Graeme Davies Building, 120 University Place, Glasgow, G12 8TA, UK

    Hugh J. Willison

Authors
  1. Hans-Peter Hartung
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Helmar C. Lehmann
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Hugh J. Willison
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Hans-Peter Hartung.

Ethics declarations

Competing interests

H.-P. Hartung has acted as a consultant for CSL Behring, Octapharma and Talecris Biotherapeutics. The other authors declare no competing interests.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Hartung, HP., Lehmann, H. & Willison, H. Establishing common clinical research standards for CIDP. Nat Rev Neurol 7, 250–251 (2011). https://doi.org/10.1038/nrneurol.2011.46

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrneurol.2011.46

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing